Abstract: The present invention relates to a continuous process for producing a haloalkenone ether of the Formula (I) wherein R1 is C1-C6 haloalkyl, R2 is a C1-C6 alkyl or phenyl, the process comprising:—(i) reacting, in a first continuous stirred tank reactor comprising a solvent, a halide of Formula (II) wherein R1 is as previously defined and R3 is halogen, with a vinyl ether of Formula (III) wherein R2 is as previously defined, to form an intermediate compound of Formula (IV), wherein the concentration of the vinyl ether of Formula (III) in the reaction mass is 15% or less w/w; and (ii) transferring the reaction mass from the first continuous stirred tank reactor into a subsequent continuous stirred tank reactor, wherein the conditions within the subsequent reactor permit the elimination of hydrogen halide (HR3) from the intermediate compound of Formula (IV) to provide the haloalkenone ether of Formula (I).

Abstract: The present invention relates to a continuous process for producing a haloalkenone ether of the Formula (I) wherein R1 is C1-C6 haloalkyl, R2 is a C1-C6 alkyl or phenyl, the process comprising:—(i) reacting, in a first continuous stirred tank reactor comprising a solvent, a halide of Formula (II) wherein R1 is as previously defined and R3 is halogen, with a vinyl ether of Formula (III) wherein R2 is as previously defined, to form an intermediate compound of Formula (IV), wherein the concentration of the vinyl ether of Formula (III) in the reaction mass is 15% or less w/w; and (ii) transferring the reaction mass from the first continuous stirred tank reactor into a subsequent continuous stirred tank reactor, wherein the conditions within the subsequent reactor permit the elimination of hydrogen halide (HR3) from the intermediate compound of Formula (IV) to provide the haloalkenone ether of Formula (I).

Abstract: There is described a process for the preparation of a compound of formula I ##STR1## in which process: a) a compound of formula II ##STR2## is reacted with an organolithium compound of formula IIILi--R.sub.7 (III)b) the resulting lithium complex is reacted with a compound of formula IVY.sub.1 --CO--CO--Y.sub.1 IVto form a compound of formula V ##STR3## c) that compound is, in either order, c1) oximated with O-methylhydroxylamine; or oximated with hydroxylamine and then methylated or fluoromethylated or difluoromethylated;c2) reacted with a chloroformic acid ester.X, m, Y, R.sub.1 to R.sub.3 and R.sub.7 are as defined in the description.

Abstract: There is described a process for the preparation of a compound of formula I ##STR1## in which process: a) a compound of formula II ##STR2## is reacted with an organolithium compound of formula IIILi--R.sub.7 (III)b) the resulting lithium complex is reacted with a compound of formula IVY.sub.1 --CO--CO--Y.sub.1 IVto form a compound of formula V ##STR3## c) that compound is, in either order, c1) oximated with O-methylhydroxylamine; or oximated with hydroxylamine and then methylated or fluoromethylated or difluoromethylated;c2) reacted with a chloroformic acid ester.X, m, Y, R.sub.1 to R.sub.3 and R.sub.7 are as defined in the description.

Abstract: Inhibitor for the glycoside hydrolases of the digestive tract, more particularly of the pancreatic .alpha.-amylase produced by fermentation of the specific microorganism Streptomyces tendae, strain 4158, as well as the variants and mutants thereof, the microbe strain per se and processes for the isolation of the inhibitor and for its purification.

Abstract: Inhibitor for the glycoside hydrolases of the digestive tract, more particularly of the pancreatic .alpha.-amylase produced by fermentation of the specific microorganism Streptomyces tendae, strain 4158, as well as the variants and mutants thereof, the microbe strain per se and processes for the isolation of the inhibitor and for its purification.

Abstract: Inhibitor for the glycoside hydrolases of the digestive tract, more particularly of the pancreatic .alpha.-amylase produced by fermentation of the specific microorganism Streptomyces tendae, strain 4158, as well as the variants and mutants thereof, the microbe strain per se and processes for the isolation of the inhibitor and for its purification.

Abstract: Acyl-aminoalkyl-benzoic acid and derivates thereof show a blood sugar lowering effect upon oral administration and can be used as orally applicable hypoglycemiants.

Abstract: Benzoic acid derivatives of the formula ##STR1## wherein T is hydrogen or halogen, W is a carboxyl group, an ester or salt thereof; X is ##STR2## wherein R.sub.1 is alkyl having from 2 to 8 carbon atoms, aralkyl or phenyl, cycloalkyl, cycloalkylalkyl or alkylcycloalkyl; R.sub.2 is hydrogen or halogen, R.sub.3 is alkyl having from 5 to 8 carbon atoms, aralkyl or phenyl, or cycloalkyl having from 5 to 8 carbon atoms; R.sub.4 is hydrogen or alkyl; Y is a single chemical bond or a hydrocarbon chain having from 1 to 3 carbon atoms; and Z is hydrogen, halogen, alkyl, alkoxy, alkoxyalkoxy or alkenyloxy, have a blood sugar lowering effect and can be used for the treatment of Diabetes mellitus.

Abstract: Benzenesulfonyl ureas of the formula ##STR1## in which R, R.sup.1, X, X.sup.1 and Y have the defined meanings, and the salts thereof, process for preparing these compounds, pharmaceutical preparations containing them and their use for lowering the blood sugar level.

Abstract: Benzenesulfonyl ureas of the formula ##STR1## in which R, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and Y have the defined meanings, and the salts thereof, process for preparing them, pharmaceutical preparations containing them and their use for lowering the blood sugar level.

Abstract: N-acylaminoalkyl-benzenesulfonyl-N'-methyl ureas, especially those of the general formula ##STR1## in which R is C.sub.1-- C.sub.4 --alkyl or a phenyl radical substituted in 2-position by alkoxy of 1 to 4 carbon atoms, phenoxy or dimethylamino and in 5-position by H, CH.sub.3, Cl or Br, their manufacture and their use as oral antidiabetics.